Choosing Between a PPI, an H2 Blocker, and an Antacid

The three classes, side by side

All three sit on the same spectrum of GERD treatment, which also includes lifestyle changes and, for cases that don't respond, surgery 1Ref 1National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020).Treatment for GER & GERD.The enumeration of GERD treatment categories: lifestyle changes, OTC and prescription antacids, H2 blockers, PPIs, and surgery for refractory cases.. The differences aren't about one being simply stronger than another — they're built around different mechanisms and different use patterns, and matching the medication to the pattern is most of what makes treatment work.

What each one is treating, mechanically

Reflux happens because the lower esophageal sphincter, the muscle that's supposed to stay closed except during a swallow, burp, or vomit, relaxes or weakens at the wrong times, or because a hiatal hernia displaces it, letting stomach acid move up into the esophagus 2Ref 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2020).Symptoms & Causes of GER & GERD.The mechanism of reflux: a weak or relaxed lower esophageal sphincter, or a hiatal hernia, letting stomach contents move upward.. None of the three medication classes fix that mechanical valve. They work downstream of it, by changing how much acid there is to reflux, or by neutralizing acid that's already made it past the valve.

An antacid treats the acid that's already in the esophagus. An H2 blocker and a PPI both treat the acid before it's made — they just block different steps in how much the stomach produces.

That distinction is why an antacid can feel more immediately satisfying — it acts on the exact acid causing the burning sensation right now — while an H2 blocker or PPI is working on tomorrow's exposure as much as today's.

When each one is the right fit

An antacid is well matched to occasional reflux — the heartburn after a particularly heavy or fatty meal, a few times a month, that resolves within a couple of hours regardless of what's done about it. It's not built to be taken on a schedule, and needing one daily is usually a sign the reflux pattern has moved past what an antacid alone should be treating.

An H2 blocker fits a step up: reflux that's frequent enough to be a nuisance, particularly at night, but not severe or constant enough to warrant the strongest acid suppression available. It's also commonly used alongside a PPI for people who get breakthrough nighttime symptoms despite a daytime PPI dose, since the two work on acid production through different pathways.

A PPI is the guideline-preferred choice for frequent, classic heartburn and regurgitation — most days, for weeks — because it's the most effective option at controlling acid long enough to let irritated tissue heal, not just to blunt a single episode.

The guideline pathway: a PPI trial before endoscopy

For someone with frequent, classic reflux and no alarm symptoms, the recommended approach is a defined eight-week trial of a once-daily PPI, taken on a fixed schedule before the first meal of the day rather than reactively when symptoms flare 3Ref 3Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric eight-week once-daily PPI trial for classic reflux without alarm features, and the indications for endoscopy done off PPI: non-response, alarm symptoms, or Barrett's risk.. If symptoms resolve, that's often treated as support for a GERD diagnosis. If they don't, or if there are alarm symptoms like difficulty swallowing, unexplained weight loss, or evidence of bleeding, the next step is endoscopy, done while off the PPI, to look directly at the esophagus 3Ref 3Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric eight-week once-daily PPI trial for classic reflux without alarm features, and the indications for endoscopy done off PPI: non-response, alarm symptoms, or Barrett's risk..

The PPI trial is meant to be a defined eight-week course on a fixed schedule, not an open-ended habit reached for whenever symptoms show up 3Ref 3Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ (2022).ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.The empiric eight-week once-daily PPI trial for classic reflux without alarm features, and the indications for endoscopy done off PPI: non-response, alarm symptoms, or Barrett's risk..

That structure — trial, then reassess — is part of what separates guideline-directed PPI use from simply taking one indefinitely because it happens to control symptoms well.

Should a PPI be taken long-term?

When a PPI is appropriately indicated, expert review concludes its benefits generally outweigh its risks over years of use, with the practical advice being to stay on the lowest dose that controls symptoms rather than to avoid the medication altogether 4Ref 4Freedberg DE, Kim LS, Yang YX (2017).The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.That appropriately indicated long-term PPI use generally has benefits that outweigh its risks, and that patients should use the lowest effective dose.. But 'appropriately indicated' is doing real work in that sentence. Separate guidance on de-prescribing recommends that people without a clear ongoing reason for a PPI attempt to stop or step down, while people with erosive esophagitis, Barrett's esophagus, or a bleeding-risk indication should generally continue 5Ref 5Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication for a PPI should attempt to stop or step down, while patients with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue..

People with erosive esophagitis, Barrett's esophagus, or a bleeding-risk indication are generally advised to continue their PPI; people without a clear ongoing reason are generally advised to try stopping or stepping down 5Ref 5Targownik LE, Fisher DA, Saini SD (2022).AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.That patients without a clear ongoing indication for a PPI should attempt to stop or step down, while patients with erosive esophagitis, Barrett's esophagus, or bleeding-risk indications should continue..

Barrett's esophagus is one of the clearest reasons to stay on a PPI rather than step down: it's a complication of chronic GERD, the only known precursor to esophageal adenocarcinoma, and guidelines recommend PPI therapy for people who have it 6Ref 6Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, Wani S (2022).Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline.That Barrett's esophagus is a complication of chronic GERD and the only known precursor to esophageal adenocarcinoma, and PPI therapy is recommended for patients with Barrett's.. For everyone else, whether long-term PPI use makes sense is a question worth revisiting with a clinician periodically, not something to decide once and never reconsider.

The practical version

Picking between these three isn't really about picking a winner; it's about matching medication to pattern, and revisiting that match if the pattern changes. Someone unsure how much heartburn is too much to keep self-treating is usually the person who should start with an antacid trial, move to a scheduled H2 blocker if that's not enough, and bring frequent or persistent symptoms to a clinician rather than escalate to a PPI alone. Understanding what gerd actually is — persistent, symptomatic reflux, not just an occasional burning sensation — is what makes that ladder make sense in the first place.

None of this means every case of heartburn is heading toward a procedure. Most reflux is well controlled by one of these three medication classes, used appropriately for the pattern it's meant for.

For reflux that doesn't settle even on an appropriately used PPI, the conversation moves beyond medication entirely: further testing, a look at barrett's surveillance if it applies, or procedural options such as the tif procedure for gerd that hasn't responded to an adequate trial. None of that is a failure of the medications — it's simply the next step in a pathway that starts with recognizing which class fits, not with picking the biggest hammer available.